Floatz logo

cd19-ucart

CD19 Positive

Shanghai Unicar-Therapy Bio-medicine Technology Co.,LtdCell therapyPhase 1/2Dormant
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

7 Active assets in the CD19 Positive cohort.

Asset / SponsorPhaseRating
Fludarabine
Jonsson Comprehensive Cancer Center
Phase 1/2B
Cyclophosphamide
Jonsson Comprehensive Cancer Center
Phase 1/2B
CARMUSTINE
M.D. Anderson Cancer Center
Phase 1/2CCC
Autologous Cd19/Cd22 Chimeric Antigen Receptor T-Cells
M.D. Anderson Cancer Center
Phase 1/2CCC
Autologous Humanized Anti-Cd22 Chimeric Antigen Receptor T Cells
M.D. Anderson Cancer Center
Phase 1/2CCC

View all 18 →

Same molecule, other indications

cd19-ucart is also rated in:

B-Cell Acute Lymphoblastic Leukemia, AdultDormant
BBB
Indicative ·
72 / 100
View asset →
B-cell non-Hodgkin lymphomaDormant
BB
Indicative ·
71 / 100
View asset →
B-cell acute lymphoblastic leukemiaDormant
BB
Indicative ·
64 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →